RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
   Small Cell Carcinoma
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Lung Channel

subscribe to Lung newsletter
Latest Research : Cancer : Lung

   EMAIL   |   PRINT
Genetic variation-Lung cancer drugs work better in the Japanese than in the Americans

Jun 3, 2007 - 3:30:28 AM , Reviewed by: Dr. Sanjukta Acharya
“Nobody else in the world has ever done this, with a common arm looking at genetic differences among ethnic groups,” Gandara says.

Key Points of this article
A study last year showed that lung cancer drugs worked better in the Japanese vs. the Americans.
Patients with variations in the CYP3A4 gene took longer for their lung cancer to progress.
Variation in another gene , ERCC2, appeared to interfere with how well patients responded to treatment.
 
[RxPG] Last year, a groundbreaking international project found that a group of Japanese patients with advanced non-small cell lung cancer survived longer —and had a higher rate of side effects — than U.S. patients with the same diagnosis,.when both groups were given two well-known drugs for the disease.

Now, a follow-up study suggests the reasons appear to lie in subtle variations in certain genes that govern how the body metabolizes chemotherapy drugs. David Gandara, M.D., a University of California, Davis researcher who led the recent Southwest Oncology Group study, presented the results Saturday, June 2, at the American Society of Clinical Oncology annual meeting.

The discovery that Japanese and U.S. patients, matched in age, gender and other respects, had differences in key metabolism-related genes is the latest result from a seven-year collaboration between the Southwest Oncology Group and two clinical trials groups in Japan. Gandara, who leads lung cancer trial efforts for the Southwest Oncology Group, is director of clinical research at the University of California, Davis, Cancer Center. The Southwest Oncology Group (SWOG) is the largest federally funded U.S. cancer trials network.

The recent SWOG study breaks new ground by exploring the possible role of ethnic patterns in the emerging science of pharmacogenomics, which promises to tailor drug regimens to a patient’s genetic profile. “Nobody else in the world has ever done this, with a common arm looking at genetic differences among ethnic groups,” Gandara says.

Researchers looked at DNA from 156 patients who received the chemotherapy drugs paclitaxel and carboplatin in a SWOG clinical trial and one conducted by the Japan Multicenter Trial Organization. In the trials, half the Japanese patients survived one year, while slightly more than one-third of U.S. patients did. The Japanese patients as a group survived longer despite the fact that a significant number of them had to be given a lower dose of paclitaxel and for a shorter time than the U.S. patients because of toxicity. The U.S. group was predominantly Caucasian; 2 percent were Asian-Americans.

To find clues to the differences, the scientists examined six genes in DNA samples from the patients. They found differences in four. In patients with certain variations in the CYP3A4 gene, it took 2.75 times longer for their lung cancer to progress than in patients without the variations. A variation in another gene, ERCC2, appeared to interfere with how well patients responded to treatment.

The differences in outcomes corresponded with the patients’ genetic makeup, rather than their ethnicity per se, since. some individuals in each group possessed genetic variations not typical of their group. Thus, the study suggests therapies in the future need to be tailored to each individual based on analysis of his or her genetic makeup, not simply ethnicity.

The relatively small number of patients makes the results of the study far from conclusive: Gandara calls the study “hypothesis-generating.” Next, he and other SWOG scientists are seeking funding to learn what genes may explain why Japanese and U.S. patients respond differently to EGFR inhibitors such as erlotinib, a relatively new targeted therapy that is another important class of drugs for lung cancer.




Advertise in this space for $10 per month. Contact us today.


Related Lung News
Tamoxifen reduces mortality rate in lung cancer
Lung Cancer risk greater in tuberculosis patients
Genes to identify patients who would benefit from chemotherapy
First-line treatment with erlotinib improved progression-free survival in advanced lung cancer
Genetic variation-Lung cancer drugs work better in the Japanese than in the Americans
Ireland Cancer Center researchers advance lung cancer treatment
Lung cancer screening regimen provides opportunity for cure
MEK inhibitors may be beneficial for lung cancer containing mutations in the BRaf gene
Potential solution to cetuximab-resistance in lung cancers
Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis

Subscribe to Lung Newsletter

Enter your email address:


 About Dr. Sanjukta Acharya
This news story has been reviewed by Dr. Sanjukta Acharya before its publication on RxPG News website. Dr. Sanjukta Acharya, MBBS is the chief editor for RxPG News website. She oversees all the medical news submissions and manages the medicine section of the website. She has a special interest in diabetes and endocrinology.
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
 Additional information about the news article
Institutions involved in the study include the Southwest Oncology Group (in addition to Gandara, members John Crowley, James Moon, Stephen K. Williamson, M.D., and Philip. C. Mack); the University of California, Davis, Cancer Center; the Japan Multinational Trial Organization; the University of Kansas, and the University of North Carolina.

The Southwest Oncology Group (www.swog.org) is the largest cancer clinical trials cooperative group in the United States. Funded by research grants from the National Cancer Institute, part of the National Institutes of Health, the group conducts clinical trials to prevent and treat cancer in adults, and to improve the quality of life for cancer survivors. The group's network of more than 5,000 physician-researchers practice at nearly 550 institutions, including 16 National Cancer Institute-designated cancer centers. Headquartered in Ann Arbor, Mich. (734-998-7130), the group has an operations office in San Antonio, Texas. and a statistical center in Seattle, Wash.

The University of California, Davis, Cancer Center, is the nation's 61st National Cancer Institute center. Its research program unites more than 275 scientists from more than a dozen disciplines on three campuses: the University of California, Davis, the UC Davis Medical Center in Sacramento, and Lawrence Livermore National Laboratory in Livermore, Calif.

 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)